Zevra Therapeutics’ MIPLYFFA receives FDA approval as first treatment for Niemann-Pick disease

Zevra Therapeutics Inc. has announced U.S. Food and Drug Administration (FDA) approval of MIPLYFFA (arimoclomol), a capsule-based treatment for Niemann-Pick disease type C (NPC), a ... Read More